A Study Conducted Over 3 Periods to Look at the Drug in the Body

• Status: Completed
• Trial end date: 2010-12-01
• Target enrollment: 0
• Participant gender: Male

Summary

A study conducted over 3 periods to look at the drug in the body.

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: AstraZeneca

Criteria

Inclusion Criteria:

• Provision of signed and dated written informed consent before any study specific procedures including consent for genetic research exploring genetic variations in CYP3A5

• suitable veins for cannulation or repeated venepuncture

• Subjects should have a body mass index (BMI) between 18 and 30 kg/m2

Exclusion Criteria:

• Abnormal vital signs (blood pressure and pulse) after 10 minutes supine rest, as judged by the investigator

• Prolonged QTcF >450 msec or shortened QTcF <350 msec or family history of long QT syndrome

• Suspicion of known Gilbert's disease

• History or presence of gastrointestinal, hepatic or renal disease or any other condition known to interfere with absorption, distribution, metabolism or excretion of drugs